通过机器学习,分子建模和体外验证来治疗癌症,发现了一种强大的氨酸特异性歇斯甲基酶-1 (LSD-1) 抑制剂
Shuya Wang1,2, Lihui Duo1, Zhangyi Ma1
1Department of Chemical and Environmental Engineering, The University of Nottingham Ningbo China, 199 Taikang East Road, Ningbo, 315100, P. R. China.
Chemistry (Weinheim an der Bergstrasse, Germany)
|October 28, 2025
概括
研究人员将L01化合物确定为氨酸特异性组织脱甲酶1 (LSD-1) 的有希望的抑制剂,这对于癌症治疗至关重要. 需要进一步优化,以提高其临床应用的生物可用性和安全性.
科学领域:
- 药用化学 医学化学
- 计算化学计算化学
- 在瘤学瘤学.
背景情况:
- 素特异性基因组脱甲酶1 (LSD-1) 的过度表达与癌症进展和恶性瘤有关.
- 针对LSD-1提供了治疗癌症治疗的治疗策略.
研究的目的:
- 通过综合计算和实验方法发现和验证LSD-1的新型抑制剂.
- 确定一种化合物,以优化癌症治疗的潜力.
主要方法:
- 基于机器学习的虚拟选,以识别候选化合物.
- 在体外酶测试和生物物理方法 (MST,SPR) 用于生物测试验证和联体-标相互作用分析.
- 分子对接,分子动力学模拟和ADMET分析用于计算验证.
主要成果:
- 虚拟查发现了29名候选人;17人显示LSD-1的微分子抑制.
- 化合物L01表现出显著的抗白血病活性 (IC50 = 24μM) 和直接与LSD-1结合.
- L01表现出有利的Caco-2透性和标特异性,与SP-2577相似的结合亲和力,但需要进一步优化药物相似性和毒性.
结论:
- 化合物L01是一种有前途的LSD-1抑制剂,具有已证明的抗白血病潜力.
- 进一步优化L01的结构是有必要的,以提高癌症治疗应用的生物可用性和安全性.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...